Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

COVID-19 viral shedding can last for up to 50 days

02 Apr 2020
The many virus pandemics in the past millennium may provide clues for the current battle against HIV/AIDS.

A new study reports a case of mild coronavirus disease 2019 (COVID-19) but with an unusually long period of viral shedding, reaching nearly 50 days.

The patient, a middle-aged man, presented with intermittent fever lasting for about 1 week. Other symptoms of COVID-19, such as stuffiness, headaches, chest pain, shortness of breath or diarrhoea, were absent. Close relatives tested positive for the infection a day prior to presentation.

Upon clinical examination, the patient had a body temperature of 36.2 oC and laboratory tests found were unremarkable, with normal levels of white blood cells, lymphocytes and neutrophils. Chest computed tomography showed signs of infection, though nasopharyngeal swabs also returned negative for influenza A and B.

The patient eventually tested positive for COVID-19 and, on days 2 to 5 of being hospitalized, developed fevers reaching just under 37.5 oC. This normalized by day 6 and, along with other disease indicators, remained stable for the remainder of hospitalization.

Routine testing on oropharyngeal swabs confirmed that the patient was positive for COVID-19 on days 17, 22, 26 and 30. Notably, the positive result persisted beyond this point, indicating viral shedding at days 34, 39 and 43. The final positive test was obtained on day 49.

Given the prolonged infection, the patient was subjected to plasma infusion, leading to high fever which subsided after a day. Subsequent viral tests returned negative.

Future studies are needed to confirm the beneficial effects of plasma therapy on COVID-19 patients and to determine the role that such prolonged viral shedding can have on the course of the outbreak, the researchers said.

This study is a preprint and is not yet peer reviewed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.